Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Imunon, Inc. (IMNN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq Capital Market issuer. Imunon is a clinical-stage biotechnology company developing DNA-mediated immunotherapies and DNA vaccine technologies, and its filings offer detailed insight into clinical progress, capital structure and listing status.
Current reports on Form 8-K are central for tracking material events. Imunon uses 8-Ks to furnish press releases on quarterly financial results, announce conference calls and webcasts, describe capital markets transactions such as at-the-market equity offerings and registered direct offerings, and report stockholder meeting outcomes. Other 8-Ks document amendments to the Restated Certificate of Incorporation, including increases in authorized common stock and the implementation of a one-for-fifteen reverse stock split, as well as Nasdaq notices regarding minimum bid price and stockholders’ equity requirements and the subsequent confirmation of regained compliance.
Through 8-K items, investors can also follow how Imunon structures its financing, such as prospectus supplements filed under existing shelf registration statements on Form S-3 and the use of sales agents for ATM programs. These filings clarify the legal framework for share issuances and warrant exercises that affect outstanding equity.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when reviewed alongside 8-Ks, provide broader context on clinical programs like IMNN-001 and IMNN-101, risk factors, and research and development spending, although these specific forms are not reproduced in the excerpts here. For insider activity, Form 4 filings would show transactions by directors and officers, complementing the governance information disclosed in proxy-related materials.
On Stock Titan, Imunon filings are updated in near real time from EDGAR, and AI-powered summaries can help explain complex sections of 10-Ks, 10-Qs and 8-Ks in plain language. This allows investors to quickly understand how corporate actions, listing compliance steps and financing decisions intersect with the company’s clinical-stage biotechnology strategy.
Imunon, Inc. files its Annual Report describing a clinical-stage pipeline and significant financial strain. The company ended December 31, 2025 with $8.8 million in cash and cash equivalents and recorded substantial doubt about its ability to continue as a going concern without new financing.
Lead ovarian cancer candidate IMNN-001 showed encouraging Phase 2 OVATION 2 results, including a final median overall survival increase of 14.7 months versus standard chemotherapy, and even larger gains when combined with PARP inhibitors. Imunon is enrolling a Phase 3 OVATION 3 trial after a favorable End-of-Phase II meeting with the FDA.
The company’s PlaCCine DNA vaccine platform also advanced, with COVID-19 booster candidate IMNN-101 demonstrating multi-fold, durable neutralizing antibody increases and good tolerability in a 24-subject Phase 1 study, though further development is currently paused while Imunon seeks partners and additional capital.
IMUNON, Inc. reported 2025 results and highlighted major advances in its ovarian cancer program. Final Phase 2 OVATION 2 data showed IMNN‑001 plus standard chemotherapy improved median overall survival to 45.1 months versus 30.4 months, and to 65.6 months versus 41.4 months when combined with PARP inhibitor maintenance, improvements the company describes as clinically meaningful.
Enrollment in the pivotal Phase 3 OVATION 3 trial remains ahead of plan. For 2025, IMUNON recorded a net loss of $14.5 million (vs. $18.6 million in 2024) as operating expenses fell 23% to $14.7 million, driven by lower R&D spending as earlier trials wound down. Year-end cash and cash equivalents were $8.8 million, supported by $17.1 million of 2025 financing, including a $7.0 million registered direct offering.
Imunon, Inc. filed a prospectus supplement to register an additional $7,000,000 of common stock under its at-the-market offering program with H.C. Wainwright & Co.
This increases the aggregate amount covered by the program to $17,000,000 of shares. Before this update, the company had already sold $4,797,848 of common stock through the sales agent under the existing agreement.
Imunon, Inc. amends its ATM prospectus supplement to increase the aggregate amount available for sale under its At the Market Offering Agreement with H.C. Wainwright & Co. to $17,000,000, adding $7,000,000 to the prior $10,000,000 authorization.
The sales program permits the company to offer and sell Common Stock from time to time pursuant to the Sales Agreement dated May 25, 2022, as amended. Through the date of this supplement the company has sold $4,797,848 under the program.
Imunon, Inc. reported that Armistice Capital, LLC and Steven Boyd beneficially own 349,917 shares of common stock, representing 9.99% of the class as of 12/31/2025. The filing states shared voting and dispositive power over the 349,917 shares and notes that the Master Fund has the right to receive dividends or sale proceeds.
Imunon, Inc. announced that Executive Vice President and Chief Scientific Officer Khursheed Anwer will retire from the company, with his employment ending on February 20, 2026. His departure is described as being without any disagreements with management.
To support continuity, Imunon and Dr. Anwer entered into a Retirement and Consulting Agreement dated February 4, 2026. From the retirement date through December 31, 2026, he will provide consulting services for a $10,000 monthly retainer, helping transition his responsibilities.
Under the agreement, Dr. Anwer will receive accrued but unpaid salary and reimbursable expenses within 30 days after his retirement date, plus continued payment of his base salary as severance for twelve months and company-paid COBRA coverage for twelve months. These benefits are conditioned on a customary release of claims in Imunon’s favor.
Imunon, Inc. filed an initial insider ownership report for its CFO, Jeffrey Wayne Church, showing his current holdings in the company. He directly holds 26 shares of common stock. In addition, he holds two stock option awards: one option to purchase 167 shares of common stock at $9.20 per share, exercisable beginning on 08/04/2025 and expiring on 08/04/2035, and another option to purchase 5,000 shares of common stock at $3.95 per share, exercisable beginning on 01/02/2026 and expiring on 01/02/2036. The options vest so that half vests on the grant date, a quarter on the first anniversary, and the remaining quarter on the second anniversary.
Imunon, Inc. reported that interim Chief Financial Officer Kimberly Graper will resign from her role effective January 14, 2026 to pursue another career opportunity. The company noted that her departure does not involve any disagreements with management and allows time for an orderly transition.
Imunon appointed Jeffrey Church, its former Executive Vice President, Chief Financial Officer and Corporate Secretary, as interim Chief Financial Officer and as its principal financial and accounting officer effective the same date. His amended consulting arrangement provides a $30,000 monthly retainer plus $250 for each hour of work above 40 hours per month during an extended consulting period that can be ended on 10 business days’ notice.
Imunon, Inc. reported an insider equity award for its CFO, Kimberly Bragg. On January 2, 2026, she received a stock option grant covering 9,050 shares of Imunon common stock at an exercise price of $3.95 per share, which the filing notes is the closing share price on the grant date. The options vest over time: one-half on the grant date, one-quarter on the first anniversary, and one-quarter on the second anniversary of the grant date. Following this grant, Bragg beneficially owns 9,050 derivative securities directly in the form of these options.
Imunon, Inc. reported an equity award to its Chief Scientific Officer, Khursheed Anwer. On January 2, 2026, he received a stock option grant covering 15,736 shares of Imunon common stock. The option has an exercise price of $3.95 per share, which matches the closing price of Imunon common stock on the grant date, and there was no cash paid for receiving the option itself.
The vesting schedule is time-based: half of the options vest on the grant date, with an additional one-quarter vesting on the first anniversary of the grant date and the remaining one-quarter vesting on the second anniversary. All 15,736 options are reported as directly owned following this transaction.